KKR has amassed a 12% stake in dental supply company Henry Schein (Nasdaq: HSIC) and taken two board seats, with the option to buy up to 2.9% more.
Why it matters: The deal could quell activist investor Ananym, which Reuters reported was pressing for a board refresh, succession planning and a sale of Henry Schein's medical distribution business.
